Literature DB >> 10811848

HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death.

S J Brodie1, B K Patterson, D A Lewinsohn, K Diem, D Spach, P D Greenberg, S R Riddell, L Corey.   

Abstract

We have tracked the in vivo migration and have identified in vivo correlates of cytotoxic T-lymphocyte (CTL) activity in HIV-seropositive subjects infused with autologous gene-marked CD8(+) HIV-specific CTL. The number of circulating gene-marked CTL ranged from 1.6 to 3.5% shortly after infusion to less than 0.5% 2 weeks later. Gene-marked CTL were present in the lymph node at 4.5- to 11-fold excess and colocalized within parafollicular regions of the lymph node adjacent to cells expressing HIV tat fusion transcripts, a correlate of virus replication. The CTL clones expressed the CCR5 receptor and localized among HIV-infected cells expressing the ligands MIP-1alpha and MIP-1beta, CC-chemokines produced at sites of virus replication. Aggregates of apoptotic cells and cells expressing granzyme-B localized within these same sites. In contrast, lymph node sections from untreated HIV-seropositive subjects, all with significant viral burden (> 50,000 HIV RNA copies/mL plasma), showed no CC-chemokine expression and exhibited only sporadic and randomly distributed cells expressing granzymes and/or apoptotic cells. These studies show that the infused CTL specifically migrate to sites of HIV replication and retain their antigen-specific cytolytic potential. Moreover, these studies provide a methodology that will facilitate studies of both the magnitude and functional phenotype of Ag-specific CD8(+) T cells in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10811848      PMCID: PMC315465          DOI: 10.1172/JCI8707

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  39 in total

1.  Control of HIV despite the discontinuation of antiretroviral therapy.

Authors:  J Lisziewicz; E Rosenberg; J Lieberman; H Jessen; L Lopalco; R Siliciano; B Walker; F Lori
Journal:  N Engl J Med       Date:  1999-05-27       Impact factor: 91.245

2.  Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency.

Authors:  D B Kohn; K I Weinberg; J A Nolta; L N Heiss; C Lenarsky; G M Crooks; M E Hanley; G Annett; J S Brooks; A el-Khoureiy
Journal:  Nat Med       Date:  1995-10       Impact factor: 53.440

3.  Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.

Authors:  M R Furtado; D S Callaway; J P Phair; K J Kunstman; J L Stanton; C A Macken; A S Perelson; S M Wolinsky
Journal:  N Engl J Med       Date:  1999-05-27       Impact factor: 91.245

4.  Pediatric AIDS-associated lymphocytic interstitial pneumonia and pulmonary arterio-occlusive disease: role of VCAM-1/VLA-4 adhesion pathway and human herpesviruses.

Authors:  S J Brodie; C de la Rosa; J G Howe; J Crouch; W D Travis; K Diem
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

5.  Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin.

Authors:  Y Merrouche; S Negrier; C Bain; V Combaret; A Mercatello; B Coronel; J F Moskovtchenko; P Tolstoshev; R Moen; T Philip
Journal:  J Clin Oncol       Date:  1995-02       Impact factor: 44.544

6.  Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes.

Authors:  T H Finkel; G Tudor-Williams; N K Banda; M F Cotton; T Curiel; C Monks; T W Baba; R M Ruprecht; A Kupfer
Journal:  Nat Med       Date:  1995-02       Impact factor: 53.440

7.  Ovine lentivirus expression and disease. Virus replication, but not entry, is restricted to macrophages of specific tissues.

Authors:  S J Brodie; L D Pearson; M C Zink; H M Bickle; B C Anderson; K A Marcom; J C DeMartini
Journal:  Am J Pathol       Date:  1995-01       Impact factor: 4.307

8.  Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation.

Authors:  C E Dunbar; M Cottler-Fox; J A O'Shaughnessy; S Doren; C Carter; R Berenson; S Brown; R C Moen; J Greenblatt; F M Stewart
Journal:  Blood       Date:  1995-06-01       Impact factor: 22.113

9.  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.

Authors:  E A Walter; P D Greenberg; M J Gilbert; R J Finch; K S Watanabe; E D Thomas; S R Riddell
Journal:  N Engl J Med       Date:  1995-10-19       Impact factor: 91.245

10.  Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics.

Authors:  M R Klein; C A van Baalen; A M Holwerda; S R Kerkhof Garde; R J Bende; I P Keet; J K Eeftinck-Schattenkerk; A D Osterhaus; H Schuitemaker; F Miedema
Journal:  J Exp Med       Date:  1995-04-01       Impact factor: 14.307

View more
  26 in total

1.  Nonmyeloablative immunosuppressive regimen prolongs In vivo persistence of gene-modified autologous T cells in a nonhuman primate model.

Authors:  C Berger; M L Huang; M Gough; P D Greenberg; S R Riddell; H P Kiem
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

Review 2.  Proving HIV-1 immunity: new tools offer new opportunities.

Authors:  L J Picker
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

3.  Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV-1 infection.

Authors:  Marcus Altfeld; Jan van Lunzen; Nicole Frahm; Xu G Yu; Claus Schneider; Robert L Eldridge; Margaret E Feeney; Dirk Meyer-Olson; Hans-Juergen Stellbrink; Bruce D Walker
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

4.  Rescue of CD8 T cell-mediated antimicrobial immunity with a nonspecific inflammatory stimulus.

Authors:  Roman A Tuma; Rielle Giannino; Patrick Guirnalda; Ingrid Leiner; Eric G Pamer
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

5.  Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes.

Authors:  L J Cooper; M Kalos; D A Lewinsohn; S R Riddell; P D Greenberg
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  Distinct kinetics of Gag-specific CD4+ and CD8+ T cell responses during acute HIV-1 infection.

Authors:  Catherine Riou; Vitaly V Ganusov; Suzanne Campion; Mandla Mlotshwa; Michael K P Liu; Victoria E Whale; Nilu Goonetilleke; Persephone Borrow; Guido Ferrari; Michael R Betts; Barton F Haynes; Andrew J McMichael; Clive M Gray
Journal:  J Immunol       Date:  2012-01-27       Impact factor: 5.422

7.  Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy.

Authors:  Tuofu Zhu; David Muthui; Sarah Holte; David Nickle; Feng Feng; Scott Brodie; Yon Hwangbo; James I Mullins; Lawrence Corey
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

8.  Dynamic regulation of functionally distinct virus-specific T cells.

Authors:  Zaza M Ndhlovu; Mathias Oelke; Jonathan P Schneck; Diane E Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-04       Impact factor: 11.205

9.  Human AdV-specific T cells: persisting in vitro functionality despite lethal irradiation.

Authors:  R Geyeregger; C Freimüller; J Stemberger; G Fischer; V Witt; G Fritsch
Journal:  Bone Marrow Transplant       Date:  2014-04-28       Impact factor: 5.483

10.  Engineering antigen-specific T cells from genetically modified human hematopoietic stem cells in immunodeficient mice.

Authors:  Scott G Kitchen; Michael Bennett; Zoran Galić; Joanne Kim; Qing Xu; Alan Young; Alexis Lieberman; Aviva Joseph; Harris Goldstein; Hwee Ng; Otto Yang; Jerome A Zack
Journal:  PLoS One       Date:  2009-12-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.